Expression of Mast Cell Proteases Correlates with Mast Cell Maturation and Angiogenesis during Tumor Progression by de Souza, Devandir Antonio, Jr. et al.
  Universidade de São Paulo
 
2012
 
Expression of Mast Cell Proteases Correlates
with Mast Cell Maturation and Angiogenesis
during Tumor Progression
 
 
PLOS ONE, SAN FRANCISCO, v. 7, n. 7, supl. 4, Part 1-2, pp. 270-274, 43282, 2012
http://www.producao.usp.br/handle/BDPI/42034
 
Downloaded from: Biblioteca Digital da Produção Intelectual - BDPI, Universidade de São Paulo
Biblioteca Digital da Produção Intelectual - BDPI
Departamento de Biologia Celular e Molecular e Bioagentes
Patogênicos - FMRP/RBP
Artigos e Materiais de Revistas Científicas - FMRP/RBP
Expression of Mast Cell Proteases Correlates with Mast
Cell Maturation and Angiogenesis during Tumor
Progression
Devandir Antonio de Souza Jr.1, Vanina Danuza Toso1, Maria Rita de Ca´ssia Campos1, Vanessa
Soares Lara2, Constance Oliver1, Maria Ce´lia Jamur1*
1Department of Cell and Molecular Biology and Pathogenic Bioagents, Faculdade de Medicina de Ribeira˜o Preto – University of Sa˜o Paulo, Ribeira˜o Preto, Sa˜o Paolo,
Brazil, 2Department of Estomatology, Faculdade de Odontologia de Bauru, University of Sa˜o Paulo, Sa˜o Paolo, Brazil
Abstract
Tumor cells are surrounded by infiltrating inflammatory cells, such as lymphocytes, neutrophils, macrophages, and mast
cells. A body of evidence indicates that mast cells are associated with various types of tumors. Although role of mast cells
can be directly related to their granule content, their function in angiogenesis and tumor progression remains obscure. This
study aims to understand the role of mast cells in these processes. Tumors were chemically induced in BALB/c mice and
tumor progression was divided into Phases I, II and III. Phase I tumors exhibited a large number of mast cells, which
increased in phase II and remained unchanged in phase III. The expression of mouse mast cell protease (mMCP)-4, mMCP-5,
mMCP-6, mMCP-7, and carboxypeptidase A were analyzed at the 3 stages. Our results show that with the exception of
mMCP-4 expression of these mast cell chymase (mMCP-5), tryptases (mMCP-6 and 7), and carboxypeptidase A (mMC-CPA)
increased during tumor progression. Chymase and tryptase activity increased at all stages of tumor progression whereas the
number of mast cells remained constant from phase II to III. The number of new blood vessels increased significantly in
phase I, while in phases II and III an enlargement of existing blood vessels occurred. In vitro, mMCP-6 and 7 are able to
induce vessel formation. The present study suggests that mast cells are involved in induction of angiogenesis in the early
stages of tumor development and in modulating blood vessel growth in the later stages of tumor progression.
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Introduction
Mast cells are gaining increased recognition as immunomodu-
lators playing a role in a wide variety of physiological processes
[1,2]. There is increasing evidence that mast cells are associated
with various types of tumors such as skin [3], breast [4], lung [5],
kidney [6], stomach [7] melanoma [8], and multiple myeloma [9].
Several of these studies correlate mast cell accumulation with
angiogenesis, suggesting that mast cells are directly related with
blood vessel formation inducing tumor progression
[10,11,12,13,14]. The tumor microenvironment likely facilitates
angiogenic responses, resulting in increased blood supply,
increased vascular permeability, and extravasation of diverse
cytokine-producing cells which may include lymphocytes, macro-
phages and mast progenitors [15,16].
One major route by which mast cells could affect various
pathways, including angiogenesis is through the effects of
mediators such as vascular endothelial growth factor (VEGF),
fibroblast growth factor (FGF), IL-8, metalloproteases, serine
proteases among others [17,18,19,20] that are stored within the
mast cell secretory granules and released upon mast cell activation
[1,21,22]. However, these mediators are not specific to mast cells
and are expressed by other cell types involved in tumor
progression. Additionally, previous studies on the role of mast
cells in tumorigenesis failed to analyze maturation of mast cell
associated with the tumor.
While mature mast cells are easily identified in tissues, immature
and very immature mast cells are difficult, if not impossible to
identify, due to the scarcity of secretory granules in these cells.
Therefore, the number of mast cells and their involvement in
tumor progression may be severely underestimated. The matura-
tion of mast cell has been divided in three distinct stages of
maturation, very immature, immature and mature. These stages
are based on heparin content, granule number and size of the mast
cells. Very immature mast cells contain few granules and do not
stain with toluidine blue. Immature mast cells have a few small
cytoplasmic granules and stain weakly with toluidine blue. In
contrast, mature mast cells have a cytoplasm replete with secretory
granules and stain strongly with toluidine blue [22,23,24]. Because
of the difficulty in identifying very immature and mature mast
cells, the contribution of mast cells to angiogenesis during tumor
progression remains unclear. Hence, the purpose of the present
study was to evaluate the role of mast cells during tumor
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progression. For this purpose tumors were induced by chemical
carcinogenesis in BALB/c mice. The recruitment of mast cells to
the tumor site as well as their stage of maturation was
characterized using mast cell specific antibodies [25], and the
expression of tryptase and chymase subtypes and carboxypepti-
dase A was analyzed during tumor progression. In addition, the
relationship between mast cells and neovascularization of the
tumor was investigated. The results show that mast cell maturation
correlates with tumor progression and angiogenesis in the skin
tumor.
Results
Skin Tumor Formation
Local administration of DMBA/TPA induced the formation of
skin tumors at 5–12 weeks of administration. Tumor progression
was divided into three morphological phases (phase I, II and III)
based on the morphological characteristics of the tumor. In the
control animals, the skin was comprised of a thin keratinized
epidermis overlying the dermis which consisted of fibrous
connective tissue with numerous glands and hair follicles. The
hypodermis, containing adipose tissue and muscle was below the
dermis (Fig. 1A). In Phase I the lesions resembled the early
follicular papilloma described by Sundberg et al. [26], and were
characterized by exophytic interfollicular epidermal proliferation
with slight hyperorthokeratosis and a granular layer, consisting of
10 to 15 layers of epithelial cells. The epidermal proliferation
included proliferation of the outer root sheath of affected hair
follicles and was above the level of the sebaceous glands. A discrete
mononuclear inflammatory infiltrate in the superficial dermis was
present, sometimes leading to a basal cell infiltration and
degeneration. The cutaneous annexes were less numerous than
in the control (Fig. 1B). In Phase II the lesions were similar to the
exophytic papilloma described by Sundberg et al. [26] with an
epidermal proliferation raised prominently above the surface of
the skin on a narrow stalk. Papillary projections of were composed
of 10 to 15 layers of proliferating epithelium and were supported
by a thin fibrovascular stroma. The granular layer and
hyperorthokeratosis were more evident. The lesions were above
the level of the sebaceous glands. Subjacent fibrous connective
tissue, were more cellularized than in the previous phase. There
was a discrete inflammation around the skin appendages which
were less numerous than in the control tissue (Fig. 1C). In Phase
III the lesions were similar to those seen in Phase II, but with
papillomatosis more pronounced. The papillary projections were
covered by 10 to 15 layers of epithelial cells and had a more
noticeable granular layer and hyperorthokeratosis, resembling the
hyperkeratotic papillomas described by Sundberg et al. [26].
Epithelial projections were supported by a fibrovascular stroma
that was denser and more cellular than that seen in the previous
phase. The lesions were above the level of the sebaceous glands.
The subjacent dermis showed less cutaneous annexes than in the
control (Fig. 1D).
Tumor progression was further confirmed by evaluating the
expression of markers of tumor progression, the integrin subunits
aV and b3 [27,28,29]. The expression of both the aV and b3
subunits were increased in phase I when compared to controls,
remained virtually unchanged in phase II, and increased again in
phase III (data not shown).
The Mast Cell Population Increases During Tumor
Progression
The mast cell population was evaluated during the three phases
of tumorigenesis. In all three stages of tumorigenesis, the stage of
maturation of granulated mast cells was determined by staining
the sections with toluidine blue and assessing the degree of
metachromasia in each mast cell. An increase in the number of
metachromatic mast cells in the dermis was observed in all three
phases of tumor progression (Fig. 2A–D). In addition, starting at
phase I, immature mast cells were observed in the dermis (Fig. 2B
inset). Immunostaining with mAb AA4, which recognizes mast
cells in all stages of maturation including very immature mast cells
that are not metachromatic, was used to identify mast cells by flow
cytometry. This analysis showed an approximately 5.5 fold
increase in the percent of AA4+ mast cells in phase I of
tumorigenesis, and an up to 8 fold increase in the percent of
AA4+ mast cells in phases II and III (Fig. 2E). While there was no
increase in the percent of total mast cells in phases II and III, the
percent of immature mast cells (Fig. 2F) increased during these
phases. The increase in histamine content during phases I-III
(Fig. 2G), reflected the increase in immature mast cells seen at
these same phases.
Mast Cell Protease Levels Change During Tumor
Progression
Although there was no difference in the number of AA4+ mast
cells during phases II and III, the histamine content increased.
Therefore, it was of interest to determine if there was an increase
in the expression of chymase, tryptase or CPA during tumor
progression mainly in phases II and III. The levels of mast cell
granule specific proteases, chymases (mMCP-4 and mMCP-5),
tryptases (mMCP-6 and mMCP-7) and mMC-CPA were analyzed
(Fig. 3). mMCP-4 was expressed in control animals and in all three
phases of tumorigenesis, but did not show differences in expression
at any phase. In contrast, mMCP-5 was expressed only during
tumorigenesis. mMCP-6 levels increased approximately two fold
during tumor progression when compared to the control. mMCP-
7 was not detected in control animals, but is expressed in phase I
and its expression increased during the late phases (II and III).
mMC-CPA had a very low level of expression in control animals,
but it increased with tumor progression. During phases II and III,
there was an increase in the expression of chymase, tryptase, and
CPA, but this was not accompanied by an increase in the number
of AA4+ mast cells.
Enzymatic Activities of Chymase and Tryptase Increase
During Tumor Progression
The increase in the levels of expression of chymase and tryptase
correlated with their enzymatic activities which increased about 4
fold during tumor progression (Fig. 4). Chymase and tryptase
activities increased progressively from phase I through phase III of
tumorigenesis. This increase in mast cell protease activity suggests
a direct involvement of mast cells in tumor progression.
Blood Vessel Number and Diameter Increase During
Tumor Progression
To correlate blood vessel formation during tumor progression,
blood vessels were immunostained for von Willebrand factor and
analyzed in histological sections (Fig. 5A). An increase in the
number of blood vessels occurred in phase I, further increased in
phase II, and remained constant in phase III (Fig. 5B). In parallel
with the increase in blood vessel number, there was also an
increase in the area occupied by blood vessels beginning in phase I
that continued through phases II and III (Fig. 5C). Additionally
the diameters of vessels were quantified and the results show that
their diameter increases in phase I and II and remains unchanged
at later phases (Figure 5D).
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Tryptase Accelerates Angiogenesis in vitro
To directly evaluate the ability of specific mast cell tryptases to
induce angiogenesis, a tube formation assay was performed using
the mouse epithelial cell line SVEC4-10. The capacity of mast cell
tryptases, mMCP-6 and mMCP-7, to increase cell spreading and
tube formation was evaluated (Fig. 6). In control cultures with no
proteases, the SVEC4-10 cells only 5.2% 63,1% were spread on
the surface (Fig. 6A). When cells were cultured for 5 h in the
presence of mMCP-6, 45.4% 69.8% of the cells were spread and
formed endothelial tubes. In the presence of mMCP-7, 90.5%
65.2% of the cells were spread or in the form of tubes (Fig. 6C).
mMCP-7 induced cell spreading and tube formation to a greater
extent than mMCP-6 (Fig. 6D).
Discussion
The present study shows that the expression of mast cell
chymase and tryptase subtypes as well as carboxypeptidase A
varies during tumor progression. Furthermore, we observed that
increased expression of these proteases correlated with mast cell
maturation and blood vessel formation, indicating their direct
involvement in skin tumor progression.
The changes in the mast cells population observed during tumor
progression suggests that total number of mast cells (mature plus
immature) increases during phase I and II and, remains stable
through phase III. The accumulation of mast cells in tumors may
be a response to the various chemoattractant factors produced by
mast cells and other cell types associated with the tumors [30]. In
vitro studies have shown that certain angiogenic factors such as
VEGF, PDGF, and bFGF are also chemoattractants for mast cells
[31]. Although several studies have shown that mast cells
accumulate around tumors [32,33], there is no information about
changes in the mast cell population or their maturation during
tumor progression. Immature mast cells initially appear at the
beginning of tumor formation and their number increases with
tumor progression. However, the increase in mediator content,
particularly in the late phases, is likely to be related to mast cell
maturation.
The role of mast cells during tumor progression can be directly
related to their granule content. Our results revealed changes in
the expression of some mast cell-specific chymases, tryptase and
carboxypeptidase A during tumor progression. Initial expression of
mMCP-5 correlated with the initiation of tumorigenesis and its
expression level increased in the later phases of tumor progression.
This increase in mMCP-5 expression may be related to mast cell
Figure 1. Tumor morphology changes with tumor progression. (A) Control –The characteristic organization and thickness of epidermis and
dermis are observed in a section of normal skin from a control mouse. (B) Phase I –This phase is characterized by epidermal proliferation, a
pronounced thickening of the dermis and the formation of a papilloma. (C) Phase II - The dermis is thicker and the papilloma is more prominent. (D)
Phase III - Keratin cysts (*) are observed, as well as a thickening of the stratum corneum.
doi:10.1371/journal.pone.0040790.g001
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Figure 2. Mature and immature mast cell numbers increase in the dermis during tumor progression. (A) Mature metachromatic mast
cells (arrow) are observed in the dermis of a control mouse. (B) At phase I a pronounced increase in mature (arrows) and immature lightly
metachromatic mast cells (arrowhead) are observed in the dermis. In phases II (C) and III (D) the number of mature (arrows) and immature mast cells
Mast Cell Proteases and Angiogenesis
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maturation. mMCP-5 is known to be one of the first mast cell
proteases expressed during maturation [34]. The results of the
present study suggest that in phase I most mast cells at the tumor
site are either very immature or immature cells that express low
levels of mMCP-5.
mMC-CPA expression also increased significantly with the
appearance of the tumor and during tumor progression. Until
recently, little information about the in vivo function of mMC-CPA
was available. Recent evidence suggests that the storage of mMC-
CPA and mMCP-5 in mast cell granules are interdependent.
mMC-CPA knockout mice, lack mMCP-5 [35], and conversely,
mice deficient in mMCP-5 lack mMC-CPA but not mMC-CPA
mRNA [36,37]. A possible explanation for the interdependence
between mMC-CPA and mMCP-5 is that they bind to each other
forming a protein complex [38] which may have functional
implications. The close association of the two proteases in the
secretory granule would facilitate substrate degradation upon
release [38]. Our results show that expression of mMC-CPA and
mMCP-5 follow a similar pattern during tumor progression and
agree with other studies in different model systems [39,40].
Lundesquist and collegues [19] have shown that chymase and
mMC-CPA cooperate in the processing of angiotensin I, thus these
protease complexes could be critical for neovascularization during
tumor progression.
mMCP-6 expression increases dramatically during tumor
progression, suggesting that this protease also has a role in the
early and late stages of tumor progression. In contrast, mMCP-7
was only detected during tumor progression, suggesting these
proteases have a pivotal role in tumor progression. Several studies
have related mast cell tryptases to enhancement of vascular
permeability [41], tissue remodeling [42] and recruitment of
inflammatory cells to a site of inflammation [43]. mMCP-6 and
mMCP-7 are functionally distinct tryptases [37,44,45]. Therefore,
these tryptase subtypes may be acting differentially during tumor
progression. Recent studies show that mMCP-6 induces neutro-
phil influx while mMCP-7 induces eosinophil influx during
infection [46]. These tryptases may also participate in the
degradation of extracellular matrix components, an event essential
for neovascularization and tumor progression [47,48].
The relationship between mast cells and tumor progression is
unclear; nevertheless, studies on tumor-associated mast cells
suggest that these cells participate in tumor progression by
promoting local angiogenesis through mediator production
[10,11,12]. The in vitro results from the current study show that
mMCP-6 and mMCP-7 are able to induce tube formation in
endothelial cells. These data suggest that both subtypes of tryptases
released from mast cells associated with the tumors may have a
direct role in neovascularization during tumor progression.
The present study shows that the expression of mast cell specific
proteases correlates with tumor progression. Furthermore, it
appears that immature mast cells are recruited to the tumor site
during the initial stages of tumor induction and mature with tumor
progression. Additionally, mast cells proteases participate in blood
vessel formation and modulation during tumor progression. They
are involved in the induction of angiogenesis at the early stages of
tumor formation and in modulating blood vessel growth in the
later stages. The results of this study provide a better understand-
ing of role of mast cell specific protease in skin tumor progression
and may lead to new therapeutic targets.
Materials and Methods
Ethics Statement
The research was conducted in accordance with ‘‘Ethical
principles in the use of experimental animals’’ adopted by the
Brazilian College of Animal Experimentation. Experimental
protocols were approved by the Commission on Ethics on Animal
Experimentation of the Faculdade de Medicina de Ribeira˜o Preto
(Protocol number 033/2007). Animals were anesthetized with
ketamine 80 mg/kg plus xylazine 12 mg/kg (Sigma-Aldrich, St.
Louis, MO) prior to experimental treatment.
Animals
Male BALB/c mice, 4–6 weeks old were used in this study.
Animals were housed and experiments were approved and
conducted according to FMRP-USP, Ribeira˜o Preto, Brazil
guidelines. Animal experiments were done in triplicate.
Tumor Production
One topical application of 100 mg of DMBA (7,12-dimethyl-
benz[a]anthracene) (Sigma- Aldrich, St Louis MO) was used to
induce chemical tumorigenesis. One week post-induction animals
were treated topically on the dorsal region with 100ml of acetone
containing 20 mg of TPA (12-O-tetradecanoilforbitol) (Sigma-
Aldrich) [49]. The TPA was further applied twice a week until the
tumor achieved the desired phase. Controls received acetone only.
Antibodies
mAb AA4 recognizes mast cell specific a-galactosyl derivatives
of the ganglioside GD1b (GUO et al. 1989; OLIVER et al. 1992).
Rabbit anti-mMCP-4, rabbit anti-mMCP-5, and rabbit anti-
mMCP-6 were kindly provided by Dr. Michael F. Gurish (Division
of Immunology, Children’s Hospital, Harvard Medical School,
Cambridge, MA). Rabbit anti-von Willebrand factor was
purchased from Millipore (Billerica, MA). Rabbit anti-integrin
aV, rabbit anti-integrin b3, goat anti-mouse mMCP-7, rat anti-
mouse mMC-CPA and rabbit anti-alpha actin were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA).The secondary
antibodies goat anti-rabbit HRP and donkey anti-rat HRP were
purchased from JacksonImmunoResearch (West Grove, PA).
Controls consisted of omitting the primary antibody or substituting
the primary antibody directly conjugated to FITC with normal
IgG from the same species conjugated to FITC.
Microscopy
Tumors were removed using a 13 mm punch. Excised tumors
were washed in PBS and fixed in 4% formaldehyde (EM
Sciences, Hatfield, PA) in PBS. The tumors were processed for
routine histology, stained with either hematoxylin and eosin or
toluidine blue (0.1%, pH2.8), and mounted on glass slides with
Permount (Thermo Fisher Scientific Inc., Waltham, MA). Some
slides were used for immunohistochemistry. Briefly, sections
mounted on glass slides were deparaffinized and rehydrated, and
endogenous peroxidase activity was blocked with 3% H202 in
methanol. Non-specific binding was blocked with PBS containing
2% BSA for 45 minutes and then samples were incubated with
the primary rabbit anti-human von Willebrand factor (10 mg/ml)
for 1 h at room temperature (RT). Following incubation, the
sections were rinsed thoroughly in PBS and the samples
(arrowheads) is higher than in phase I. Inset in phase I show an immature mast cell (Toluidine blue). (E) Flow cytometry analysis of mast cells during
tumor progression using AA4-FITC. (F) The percentage of immature mast cells is increased at phase I of tumor progression and continues to increase
during the phases II and III. (G) Histamine content also increased during tumor progression. (n = 3) *P,0.05.
doi:10.1371/journal.pone.0040790.g002
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incubated with anti-rabbit IgG conjugated to HRP (Jackson
ImmunoResearch) for 45 minutes. After which, the slides were
rinsed thoroughly in PBS and incubated with 3,39-diaminoben-
zidine and H202 for 15 minutes, mounted with Permount.
Samples were observed using an Olympus BX-50 microscope
(Olympus America Inc., Melville, NY) equipped with a Nikon
DXM-1200 digital camera (Nikon USA, Melville, NY).
Tumor Dissociation
The tumors were dissociated according to the method of
Bradshaw [50], with modifications. Briefly, the tumors were
harvested and placed into sterile 6 wells plates containing 0.6
units/ml of trypsin (Worthington Biochemical Corp, Lakewood,
NJ) in dissection buffer (10 mM glucose, 3 mMKCl,
130 mMNaCl, 1 mM Na2HPO4, 30 mM HEPES, pH 7.4) and
incubated overnight at 4uC. After incubation the epidermis was
separated from the dermis. The dermis underwent further
digestion with 750units/ml of type IV collagenase (Worthington)
in DMEM for 3 h at 37uC. The cells were filtered through 25 mm
nylon mesh and the cell suspension was centrifuged at 240 g at 4uC
for 10 minutes. The supernatant was discarded; the pellet
resuspended in PBS and the cells used for flow cytometry.
Flow Cytometry
After dissociation cells were fixed with 2% formaldehyde (EM
Sciences) blocked with PBS containing 1% BSA (Sigma-Aldrich)
for 45 minutes and incubated with mAb AA4 (5 mg/ml) for 1h
conjugated to FITC (Jackson ImmunoResearch). Following
incubation, cells were washed by centrifugation at 240 g in PBS
and analyzed by flow cytometry using a Becton-Dickinson
FACSCaliburTM (Becton-Dickinson Biosciences; Bedford, MA)
with CELLQuest software.
Tumor Lysate
Tumor lysates were prepared using a modification of the
ProSciIncoporated Protocol (Poway, CA). Tumors were removed
using a 13 mm punch and then homogenized in lysis buffer
(10 mM HEPES pH7.9, 1.5 mM MgCl2, 10 mM KCl, 1 mM
EDTA, 10% glycerol, 1% NP-40, and 15 ml of protease inhibitor
cocktail [Sigma-Aldrich]) using an Ultra80 Homogenizer (Ultra
Stirrer, Eikonal do Brasil, Sa˜o Paulo, SP). Tissue and cell debris
were removed from the lysate by centrifugation (2 800 g/4uC/
30minutes). The protein concentration of the supernatant was
determinate using a BCA Protein Assay Kit (Pierce, Thermo
Fisher Scientific, Rockford, IL).
Immunoblotting
20 mg of lysate were boiled for 5 minutes in 16 SDS sample
buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium
dodecylsulfate, 0.01% bromophenol blue), and applied to10%
polyacrylamide gels. Proteins were then separated electrophoret-
ically and transferred to Hybond membranes (GE Healthcare,
Piscataway, NJ). Membranes were blocked overnight in TBS
(0.05 M Tris–HCl, 0.15 M NaCl, pH 7.5, and 0.05% Tween 20)
containing 5% nonfat dry milk at 4uC. Membranes were then
incubated with anti-protease antibodies (mMCP-4, mMCP-5,
mMCP-6, mMCP-7 and mMC-CPA) at 1:200 or rabbit anti-
integrin aV, rabbit anti-integrin b3, for 1 h at RT, washed in
TBS/Tween and incubated with goat anti-rabbit IgG conjugated
to HRP or goat anti-rat IgG conjugated to HRP (1:20,000)
(JacksonImmunoResearch) for 30 minutes at RT, washed and
developed using chemiluminescence (ECL-GE Healthcare, Piscat-
away, NJ). Alpha-actin was used as a loading control. The blots
Figure 3. Expression of chymase, tryptase and carboxypeptidase A were altered during tumor progression. Western blots of cell lysate
from control, phases I, II and III of tumor progression. The levels of mMCP-4 are constant in the 3 phases. mMCP-5 is only expressed during
tumorigenesis. The levels of mMCP-6 increase progressively during the three phases. mMCP-7 was not detected in control animals, begging to
expression in phase I and remained unchanged in phases II and III. The expression of mMC-CPA is almost not detectable in controls, but increases in
phases I and II, and remains unchanged in phase III. Alpha-actin was used as a loading control. Mean optical density of blots presenting the data of
the mean values 6 SEM of 3 independent experiments. *P,0.05.
doi:10.1371/journal.pone.0040790.g003
Figure 4. Enzymatic activity of chymase and tryptase increase
with tumor progression. The activities of both chymase and tryptase
increase mainly in phases II and III. The data represent the mean values
6 SEM. (n = 3) *P,0.05.
doi:10.1371/journal.pone.0040790.g004
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were scanned, and the optical densities of the bands were
calculated using Adobe Photoshop (Adobe Systems, San Jose, CA).
Histamine Assay
Histamine assays were performed as previously described [51].
Briefly, the histamine was extracted into n-butanol from alkalinized
perchloric acid tissue extracts. The histamine was returned to an
aqueous solution and condensed with o-phthalaldehyde (Sigma-
Aldrich) to yield a fluorescent product. The intensity of fluorescence
was measured using the Histamine Module for the Trilogy
Laboratory Fluorometer (Turner Designs, Inc., Sunnyvale, CA).
Chymase and Tryptase Activity
Chymase activity was determined using the Chymase Assay Kit
(Sigma-Aldrich) using the mast cell specific substrate the N-benzol-
L-Tyrosine ethyl ester (BTEE) and read at 256 nm. Tryptase
activity was determined using the Mast Cell Degranulation Assay
Kit (Millipore) with the mast cell specific substrate the tosyl-gly-
pro-lys-pNA with substrate and measured at 405 nm. For these
assays, lysates were prepared at 4uC without protease inhibitors
and stored at 280uC until use. There was no difference in mg
protein/ml between lysates prepared with or without protease
inhibitors. Both assays were evaluated using an Elisa Power Wave
X Plate Reader (Bio-Tek Instruments, Inc., Winooski, VT).
Blood Vessel and Mast Cell Quantification
Vessel counting was performed as described by Weidner [52].
After immunostaining with von Willebrand factor, each slide was
screened using a 206objective to identify the center of the tumor. An
area of 1,9 mm2 was delineated using the center of the tumor as a
marker. The total number of vessels, their area and diameter were
determined in a delineated region for three slides per animal. The
vessel count for each animal was expressed as the average number of
vessels from five different slides. The area covered by vessels as well as
their diameter was determined in the same fields screened for vessel
counts. The percentage of the area covered by vessels in each animal
was expressed as the mean from the five slides analyzed. The area of
each blood vessel was determined using Image-Pro Plus, v 5.5.1.38
(MediaCybernetics, Bethesda, MD). Mast cells were counted after
staining sections with toluidine blue. The same procedure was used to
quantify toluidine blue mast cells as was used for blood vessels. This
procedure was used for quantifying randomly selected areas of the
dorsal derme of control animals.
In vitro Assays
The murine endothelial cell line SVEC4-10 was purchased from
the American Type Culture Colletion (Manassas, VA). The cells
were maintained in DMEM (Invitrogen Corporation, Carlsbad,
CA) plus 10% fetal bovine serum in a humidified environment
containing 5% CO2 in air. Geltrex
TM (Invitrogen) was added to
the wells (200 ml/well) of 24 well plates and allowed to solidify at
37uC for 30 minutes, then 46104 cells in 200 ml of DMEM were
placed in each well and incubated at 37uC for 5 h with or without
20 ng of tryptase (mMCP-6 or mMCP-7, R&D Systems Inc.,
Minneapolis, MN). SVEC4-10 cells spontaneously spread and
undergo tube formation. The ability of the cells to form
endothelial tubes in the presence or absence of tryptases were
evaluated by phase contrast microscopy using a Nikon Eclipse
TS100 inverted microscope equipped with a Nikon DXM-1200
digital camera (Nikon).
Figure 5. Blood vessel number and diameter increase during tumor progression. (A) Representative sections of control skin and tumors
during Phases I, II and III demonstrating the increase in the number and diameter of blood vessels (arrows) with tumor progression. Blood vessels
were immunostained for von Willebrand factor. (B) The number of blood vessels, (C) the percentage of area covered by blood vessels and (D) the
diameter of the vessels increases considerably in phase I and II and remains constant in phase III. (n = 3) *P,0.05.
doi:10.1371/journal.pone.0040790.g005
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Statistical Analysis
Values areexpressedas themean6SD.Student’s t-testwasused to
compare tumor phases. P-values of ,0.05 were considered signifi-
cant. The data are means from three independent experiments.
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Figure 6. Mast cell proteases induce cell spreading and tube formation in SVEC4-10 cells. (A) When cells were incubated in absence of
proteases, only a few cells were spread on the surface, beginning to form tubes (arrow) and most of the cells remained unspread. (B) mMCP-6
augments cell spreading and tube formation in comparison to the control cultures (arrows). (C) mMCP-7 is more efficient in inducing cell spreading
and tube formation than mMCP-6. Most of cells are spread (arrowhead) or in the form of tubes (arrows). Phase contrast microscopy. (D) The graphics
show the percent of cells that were spread on the surface (GeltrexTM) after 5 h incubation. *P,0.05.
doi:10.1371/journal.pone.0040790.g006
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